290 related articles for article (PubMed ID: 12236626)
21. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
Fava M; Rosenbaum JF; Hoog SL; Tepner RG; Kopp JB; Nilsson ME
J Affect Disord; 2000 Aug; 59(2):119-26. PubMed ID: 10837880
[TBL] [Abstract][Full Text] [Related]
22. Cognitive and psychomotor effects of paroxetine and sertraline on healthy elderly volunteers.
Furlan PM; Kallan MJ; Ten Have T; Pollock BG; Katz I; Lucki I
Am J Geriatr Psychiatry; 2001; 9(4):429-38. PubMed ID: 11739070
[TBL] [Abstract][Full Text] [Related]
23. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
Stahl SM
Biol Psychiatry; 2000 Nov; 48(9):894-901. PubMed ID: 11074227
[TBL] [Abstract][Full Text] [Related]
24. Selective serotonin reuptake inhibitor usage patterns as risk factors for hospitalization.
Sheffield RE; Lo Sasso AT; Young CH; Way K
Adm Policy Ment Health; 2002 Nov; 30(2):121-39. PubMed ID: 12680617
[TBL] [Abstract][Full Text] [Related]
25. Are paroxetine, fluoxetine, and sertraline equally effective for depression?
Straton JB; Cronholm P
J Fam Pract; 2002 Mar; 51(3):285. PubMed ID: 11978244
[No Abstract] [Full Text] [Related]
26. Duration of therapy and health care costs of fluoxetine, paroxetine, and sertraline in 6 health plans.
Polsky D; Onesirosan P; Bauer MS; Glick HA
J Clin Psychiatry; 2002 Feb; 63(2):156-64. PubMed ID: 11874218
[TBL] [Abstract][Full Text] [Related]
27. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
28. Treating functional impairment of autism with selective serotonin-reuptake inhibitors.
Moore ML; Eichner SF; Jones JR
Ann Pharmacother; 2004 Sep; 38(9):1515-9. PubMed ID: 15292500
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneity of SSRI response.
Salzman C
Harv Rev Psychiatry; 1996; 4(4):215-7. PubMed ID: 9384996
[No Abstract] [Full Text] [Related]
30. Serotonergic autoreceptor blockade in the reduction of antidepressant latency: personality variables and response to paroxetine and pindolol.
Tome MB; Cloninger CR; Watson JP; Isaac MT
J Affect Disord; 1997 Jul; 44(2-3):101-9. PubMed ID: 9241570
[TBL] [Abstract][Full Text] [Related]
31. Targeted pharmacotherapy in depression management: comparative pharmacokinetics of fluoxetine, paroxetine and sertraline.
Preskorn S
Int Clin Psychopharmacol; 1994 Jun; 9 Suppl 3():13-9. PubMed ID: 7963446
[TBL] [Abstract][Full Text] [Related]
32. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline.
Waldinger MD; Hengeveld MW; Zwinderman AH; Olivier B
J Clin Psychopharmacol; 1998 Aug; 18(4):274-81. PubMed ID: 9690692
[TBL] [Abstract][Full Text] [Related]
33. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
34. Selective serotonin reuptake inhibitor-induced mydriasis.
Larson M; Folstein S
J Am Acad Child Adolesc Psychiatry; 2000 Feb; 39(2):138-9. PubMed ID: 10673818
[No Abstract] [Full Text] [Related]
35. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
Aberg-Wistedt A; Agren H; Ekselius L; Bengtsson F; Akerblad AC
J Clin Psychopharmacol; 2000 Dec; 20(6):645-52. PubMed ID: 11106136
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study.
Bertani A; Perna G; Arancio C; Caldirola D; Bellodi L
J Clin Psychopharmacol; 1997 Apr; 17(2):97-101. PubMed ID: 10950471
[TBL] [Abstract][Full Text] [Related]
37. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
38. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report.
Uguz F; Sonmez EÖ
Gen Hosp Psychiatry; 2013; 35(3):327.e7-327.e8. PubMed ID: 23312145
[TBL] [Abstract][Full Text] [Related]
39. Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area.
Di Mascio M; Di Giovanni G; Di Matteo V; Prisco S; Esposito E
Brain Res Bull; 1998 Aug; 46(6):547-54. PubMed ID: 9744293
[TBL] [Abstract][Full Text] [Related]
40. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms.
Ferrando SJ; Goldman JD; Charness WE
Gen Hosp Psychiatry; 1997 Mar; 19(2):89-97. PubMed ID: 9097063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
